抗病毒免疫
Search documents
Nature:成纤维网状细胞通过CD44指导T细胞应答的启动,而病毒能够劫持这一过程
生物世界· 2026-01-26 07:00
撰文丨王聪 编辑丨王多鱼 排版丨水成文 在次级淋巴器官内, 树突状细胞 和 T 细胞 的移动,对于适应性免疫反应的形成至关重要。这一过程的核 心是 成纤维网状细胞 (FRC) 网络 ,它形成了一套高度有序的管道系统 ,有助于树突状细胞和 T 细胞的 移动以及它们之间的相互作用。 之前的研究已在一定程度上阐明了 FRC 是如何支持这些相互作用的,然而,其在生理条件下发挥作用的分 子机制,目前仍不清楚。 2026 年 1 月 21 日,莫纳什大学的研究人员在 Nature 期刊发表了题为: Fibroblastic reticular cells direct the initiation of T cell responses via CD44 的研究论文。 该研究表明, 成纤维网状细胞 (FRC) 通过 CD44 指导 T 细胞应答的启动,而 巨细胞病毒 (CMV) 能 够通过产生 m11 蛋白来结合并阻断 CD44,从源头上扰乱免疫细胞的移动,从而削弱抗病毒反应。 这一发现揭示了一种病毒免疫逃逸新机制,从根本上改变了我们对于塑造免疫功能的信号的理解。 病毒 会劫持细胞功能以利己。在长期共同进化的过程中,病毒 ...
Cell子刊:宋相容/刘继彦团队开发树突状细胞靶向的mRNA纳米疫苗,增强抗病毒免疫
生物世界· 2025-08-26 04:03
Core Viewpoint - mRNA vaccines represent a transformative advancement in immunology, characterized by rapid production and strong immunogenicity across various disease conditions [3][4]. Group 1: mRNA Vaccine Technology - The use of lipid nanoparticles (LLN) has emerged as a versatile and efficient delivery vehicle, enhancing stability and adaptable surface chemistry for the development of effective and low-toxicity targeted mRNA vaccines [3]. - mRNA vaccines generate robust and long-lasting protective immunity, primarily through antigen-presenting cells (APC), particularly dendritic cells (DC), which efficiently present antigens and optimally localize to lymphoid tissues [4]. Group 2: Challenges in Vaccine Delivery - Direct targeting of dendritic cells significantly improves vaccine efficacy; however, non-specific uptake by macrophages during in vivo vaccine delivery poses a major challenge [4]. - Despite macrophages' phagocytic capabilities, their ability to transport antigens from peripheral tissues to lymphoid tissues for effective initial T cell stimulation is limited [4]. - Reducing macrophage-mediated uptake of nanoparticle vaccines is crucial for promoting lymph node transport and ultimately enhancing vaccine efficacy [4]. Group 3: Research Development - On August 18, 2025, a collaborative research paper titled "A precision-engineered dendritic cell-targeted mRNA nanovaccine for enhanced antiviral immunity" was published by teams from Sichuan University, led by Song Xiangrong and Liu Jiyan, in the journal Cell Biomaterials [4].